How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,400 results for

Six Item Cognitive Impairment Test


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

compulsive disorder. This study represents an innovative approach in translating bench research findings into clinical research and testing a new approach for optimizing an effective psychotherapy with a safe non-psychotropic medication. Condition or disease Intervention/treatment Phase Obsessive-compulsive Disorder Behavioral: Cognitive-behavioral therapy Drug: d-cycloserine Drug: Pill placebo Phase 3 Detailed Description: Obsessive-compulsive disorder (OCD) affects 1-2% of children, runs a chronic (...) course without treatment, and is associated with considerable functional impairment and poor quality of life. Although most patients with OCD respond to cognitive-behavioral therapy (CBT) or pharmacotherapy with a serotonin reuptake inhibitor (SRI), a substantial number of youth remain symptomatic after receiving these therapies. Pharmacological interventions with SRIs are only moderately efficacious, rarely produce remission, may be accompanied by side effects, and may not be an acceptable

2011 Clinical Trials

162. 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

impairment). Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale [ Time Frame: Days 1 (baseline) and 91 ] Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort (...) in brain glucose utilization, using FDG-PET voxel-based analysis. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. Explore

2011 Clinical Trials

163. The Effect of Rasagiline on Cognition in Parkinson's Disease

: Placebo Participants in this group will receive 1 mg of placebo daily for the six month duration of the study. Drug: Placebo 1 mg daily Outcome Measures Go to Primary Outcome Measures : Rey Auditory Verbal Learning Test [ Time Frame: Change in score from day 1 of study enrollment and score after 6 months of treatment ] This is a 15 item supraspan verbal memory test. This measure assesses immediate memory span, new learning, susceptibility to interference, retention, and recognition memory. Secondary (...) . Frakey, Brown University Study Details Study Description Go to Brief Summary: While Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkinson's disease. These deficits are often subtle and do not rise to the level of impairment necessary for a diagnosis of dementia; however these deficits are discernable

2011 Clinical Trials

164. Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder

(in the patient's and clinician's opinion) and the primary reason for seeking treatment Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale Exclusion Criteria: Current clinically significant suicidality and/or score on the BDI-II suicide item (#9) > 1 Any clinical features requiring a higher level of care Mental retardation or borderline intellectual functioning (estimated IQ < 80 on the Wechsler Abbreviated Scale of Intelligence) or dementia, brain damage, or other cognitive impairment (...) chronic, and common disorder consisting of distressing or impairing preoccupation with perceived defects in one's physical appearance. Individuals with BDD have very poor psychosocial functioning and high rates of hospitalization and suicidality. Because BDD differs in important ways from other disorders, psychotherapies for other disorders are not adequate for BDD. Despite BDD's severity, there is no adequately tested psychosocial treatment (psychotherapy) of any type for this disorder. This study

2011 Clinical Trials

165. Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

scan performed in the last six months. Patients with cognitive impairment at screening, defined as at least one test of the Rao's Brief Repeatable Battery with scores falling outside the 90th percentile of the normative data. Exclusion Criteria: Patients who had already been treated with multiweekly interferon (interferon beta 1b, or beta 1a multiweekly) and had an unsatisfactory response according to the judgment of the investigator. Patients with hyperactive forms of the MS disease according (...) ): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive

2011 Clinical Trials

166. Canadian Stroke Best Practice recommendations: rehabilitation, recovery, and community participation following stroke. Part one: rehabilitation and recovery following stroke; 6th edition update 2019

and rehabilitation care, in a subgroup analysis of three trials that compared stroke rehabilita- tion units speci?cally versus an alternative service, the odds of death at end of follow-up were reduced signi?- cantly. Although the odds of death or institutionaliza- tion dependency, death or dependency, and hospital length of stay (LOS) were not reduced, small sample sizes may have driven the null result. b. Additional screening of impairments, including onset of depression, cognitive ability, functional activity (...) strokeisthe reduction of arm, hand and wrist arm function due to weaknessorhemiplegia,whichlimitsfunction.Theresult- ingimpairmentsreduceaperson’sabilitytoperformbasic ADLsandmaycausepainandreducedrangeofmotion (ROM). While almost three-quarters of persons with stroke will present with upper-limb impairment, only 5– 20% of persons can expect to achieve full functional recovery six months following stroke. 24 Persons who experience mild to moderate upper extremity paresis

2020 CPG Infobase

167. Continual Long-Term Physiotherapy After Stroke

is expected to increase by 80% over the next two decades because of the aging population and improvements in acute care. 2 Each year, more than 50,000 people in Canada are estimated to have a first stroke. A majority of strokes occur in people over the age of 65 years. 3 Most people (83%) survive their first stroke, but with substantial morbidity. 4 It is common for people to experience weakness of the upper and lower limbs after stroke, in addition to a loss of cognitive functions. This weakness can (...) Series; Vol. 20: No. 7, pp. 1–70, March 2020 9 people should be assessed by an interprofessional team and that people “with residual impairment identified as having further rehabilitation needs should receive therapy services to set new goals and improve task-oriented activity.” 16 The clinical handbook also recommended that patients be given two to three physiotherapy sessions each week for 8 to 12 weeks (combined with community-based clinic services, including from hospitals, whenever appropriate

2020 Health Quality Ontario

168. 10-kHz High-Frequency Spinal Cord Stimulation for Adults With Chronic Noncancer Pain

are placed and programming protocols are tested on a temporary pulse generator to determine patients’ reactions and preferences. If the trial is successful—usually defined as a 50% or greater reduction in a patient’s pain intensity over baseline—the pulse generator is implanted permanently. Health Technology Under Review High-frequency SCS is a new subtype of SCS for chronic pain that emits electrical pulses in kilohertz, exceeding the range of low-frequency SCS (i.e., is greater than 200 Hz (...) Committee recommended increased access to low-frequency SCS as part of comprehensive pain management for chronic noncancer pain. 22 Six designated centres of excellence in Ontario currently offer SCS (neuromodulation) for chronic pain: St. Michael’s Hospital and the University Health Network in Toronto; Hamilton Health Sciences; London Health Sciences Centre; Kingston Health Sciences Centre; and the Ottawa Hospital. At present, physicians who implant SCS devices include pain physicians

2020 Health Quality Ontario

169. Implantable Devices for Single-Sided Deafness and Conductive or Mixed Hearing Loss

,ab,kf. (13725) 12 (osseointegrat* or osseo integrat*).ti,ab,kf. (17194) 13 or/9-12 (53118) 14 Hearing Aids/ (18308) 15 Correction of hearing impairment/ (4562) 16 (hearing adj3 (aid*1 or device* or system* or implant* or technolog*)).ti,ab,kf. (22689) 17 or/14-16 (30846) 18 13 and 17 (2628) 19 (Bonebridge* or Soundbridge*).ti,ab,kf. (568) 20 ((BAHA or BAHAs or BAHS or BAHSs or BAHI or BAHIs or BAHD or BAHDs or BCHI or BCHIs) adj5 (cochlea* or implant* or device* or system*1)).ti,ab,kf. (629) 21 (...) ) Appendices March 2020 Ontario Health Technology Assessment Series; Vol. 20: No. 1, pp. 1–165, March 2020 121 14 Hearing Aids/ (18472) 15 Correction of hearing impairment/ (4607) 16 (hearing adj3 (aid*1 or device* or system* or implant* or technolog*)).ti,ab,kf. (23176) 17 or/14-16 (31334) 18 13 and 17 (2650) 19 (Bonebridge* or Soundbridge*).ti,ab,kf. (569) 20 ((BAHA or BAHAs or BAHS or BAHSs or BAHI or BAHIs or BAHD or BAHDs or BCHI or BCHIs) adj5 (cochlea* or implant* or device* or system*1)).ti,ab,kf

2020 Health Quality Ontario

170. Suicide postvention services

for Quantitative Studies. 57 The NHMRC Levels of Evidence comprises six levels of evidence based on the design of the study (Appendix 1, Table 7). Systematic reviews of randomized controlled trials (RCTs) are considered the highest level of evidence (Level I). Case series, with post-test or pre- and post-test outcomes are at the bottom of the evidence hierarchy (Level IV). The NHMRC instrument also requires a summary of the body of evidence of five components: evidence-base (e.g., number and quality (...) of the studies), consistency of findings across studies, clinical impact, generalizability of findings, and applicability in the Australian or local context (Appendix 1, Table 8). Two researchers (NR, KA) independently assessed the levels of evidence, and settled any disagreement through discussion. The Quality Assessment Tool for Quantitative Studies 57 comprises six components (selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts) which are scored

2020 Sax Institute Evidence Check

171. Polyvalent immunoglobulins – Part 1: A rapid review

products, when efficacy is established in immune trombocytopenia (ITP), the licence/registration is extended to other immunomodulating indications GBS, Kawasaki, MMN and CIPD, without the need to perform separate clinical trials (this new EMA guideline came into effect in 2019). 25, 26 Mostly because of the immunomodulating properties the list of possible indications and off-label use keeps growing. The exact working mechanism of Ig is not fully elucidated. Therefore, Ig are often used and tested (...) studied (no limit on indications). The clinical research question was formulated using the PICOS (Participants-Interventions-Comparator-Outcomes-Study Design) framework (see Table 2). Because polyvalent Ig are used for a wide range of indications covering different medical domains such as haematology, neurology, immunology, dermatology, paediatrics… the search strategy items were defined broadly (e.g. no restriction on population and age, different comparators and outcomes dependent on the indication

2020 Belgian Health Care Knowledge Centre

172. Risk reduction and management of delirium

onset (hours, days) of acute mental status deterioration. Patients may present with cognitive impairment, but drowsiness to the point that the patient is not speaking, severe agitation, or psychotic features such as hallucinations or delusions may be the most prominent features. Delirium is sometimes described using hyperactive, hypoactive or mixed labels depending on the level of arousal. 13 Most delirium has a duration of a small number of days, but in around 20% of cases, it can persist for weeks (...) Scale; SQiD – Single Question to Identify Delirium Tool Time taken (min) Training Required Staff Settings Reported Sensitivity % Reported Specificity % Delirium severity rating Suitable for monitoring Suitable for detecting DSD 4AT 20,24,26,27,30,32 80 years in the majority of studies in the systematic review). 125,127-129 The studies addressed a variety of population groups, in acute and ICU settings, and used different measures for delirium, mental and cognitive impairment and depression. R

2019 SIGN

173. Guidelines for diagnosing and managing pediatric concussion

:// Accessed May 8, 2014. 2 Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56. Chapter: Tipsheet Guidelines for Diagnosing and Managing Pediatric Concussion 3 Tipsheet / List of Tools Tipsheet for Health Care Professionals In Advance (before the first activity) Number Evidence 0.4 Consider baseline neuro-cognitive testing (...) for Diagnosing and Managing Pediatric Concussion 5 Tipsheet / List of Tools 5.4c(i) Assess for persistent cognitive difficulties. B 5.4c(ii) Manage any cognitive impairments. B 5.4d(i) Assess for balance and vestibular impairments. B 5.4d(ii) Assess for benign positional vertigo. B 5.4d(iii) Refer for further assessment and treatment if balance and/or vestibular system are dysfunctional. B 5.4e(i) Assess ongoing vision dysfunctions. B 5.4e(ii) Refer children/adolescents who have changes in functional vision

2019 CPG Infobase

174. Optimisation of RIZIV – INAMI lump sums for incontinence

evaluation and management 40 2.4.6 Care pathway for the management of urine incontinence in men 41 2.4.7 Care pathway for the management of urine incontinence in women 45 2.5 MANAGEMENT OF URINARY INCONTINENCE IN THE FRAIL ELDERLY AND THE COGNITIVELY IMPAIRED 49 2.5.1 Conservative options 49 2.5.2 Pharmacological treatment 50 2.5.3 Surgical treatment in the frail older person 52 2.6 MANAGEMENT OF URINARY INCONTINENCE IN CHILDREN 56 2.6.1 Initial assessment 56 2.6.2 Initial management 57 2.6.3 Specialised (...) and severe dementia are individual risk factors for UI. Overflow of urine commonly presents when the bladder is continuously full, with or without weakening of the bladder muscles, and when there is no urge to urinate or bladder contractions. Predisposition factors for UI in men are less well documented in the literature and include presence of lower urinary tract symptoms (LUTS), urinary tract infections, functional and cognitive impairment, diabetes, neurological disorders, and surgery e.g

2020 Belgian Health Care Knowledge Centre

175. Health literacy: what lessons can be learned from the experiences of other countries?

Mannaerts (Cultures et santé), Emmanuelle Nijs (Koning Boudewijnstichting – Fondation Roi Baudouin), Maryse Van Audenhaege (Landsbond der Christelijke Mutualiteiten), Martine Van Hecke (Test Aankoop), Tinne Vandesande (Koning Boudewijnstichting – Fondation Roi Baudouin), Rebekka Verniest (Landsbond der Christelijke Mutualiteiten) External validators: Gilles Henrard (ULg – Université de Liège), Diane Levin-Zamir (Clalit Health Services, Israel), Orkan Okan (Universität Bielefeld) Acknowledgements: Jamie (...) : Valérie Fabri (UNMS), Siska Germonpré (Staff member NVSM), Martine Van Hecke (Test Aankoop) Participation in scientific or experimental research as an initiator, principal investigator or researcher: Tine Vandesande (Selection of health literacy projects supported by the Fonds Daniël De Coninck) Layout: Joyce Grijseels, Ine Verhulst Disclaimer: • The external experts were consulted about a (preliminary) version of the scientific report. Their comments were discussed during meetings. They did not co

2020 Belgian Health Care Knowledge Centre

176. A palliative approach to care in the last 12 months of life

the recommendations. As there are numerous accessible palliative care and end-of-life care resources this section includes a sample published within the last five to six years and that aligns with the recommendations (with the exception of unique or seminal publications). Content listed in this section was not part of the systematic review and was not quality appraised. As such, the list is not exhaustive, and the inclusion of a resource in one of these lists does not imply an endorsement from RNAO. Note

2020 Registered Nurses' Association of Ontario

177. What works to improve early grade literacy in Latin America and the Caribbean? A systematic review and meta?analysis Full Text available with Trip Pro

that had an emphasis on EGL outcomes but did not emphasize a specific intervention, 14 qualitative studies without a focus on a specific intervention, and six qualitative studies that focused on a specific intervention. Most of the studies included in our review of evidence were published journal articles and came from either Mexico or South America; significantly fewer articles were from Central America and the Caribbean. Almost all articles were published in English or Spanish. More than 90 (...) in the lowest level of the reading test, and <5% of the third graders performed so well that they were categorized as achieving the highest levels of reading. Figure depicts these challenges by demonstrating that there are still a significant number of third graders scoring at the lowest levels of reading. In fact, more than 60% of third‐grade students have only achieved basic reading skills (Levels 1 and 2). Figure 2 Percentage of third graders scoring at level 1 or below on reading, 2013. (1) Lowest

2019 Campbell Collaboration

178. The promotion of well?being among children exposed to intimate partner violence: A systematic review of interventions Full Text available with Trip Pro

and the SD of the mean change in each group; (d) group means and paired t statistics for each group; (e) group means and between‐group t statistic; and (f) between‐group t statistic only. Examples of intervention effects that were reported on a continuous scale include internalizing and externalizing distress (e.g., behavioral checklist raw scores), total problems (e.g., behavioral checklists raw scores), and cognitive functioning (e.g., intelligence test total score). Examples of dichotomous outcomes (...) health problem. An estimated 8–15 million children in the United States (Hamby, Finkelhor, Turner, & Ormrod, ; McDonald, Jouriles, Ramisetty‐Mikler, Caetano, & Green, ) and 275 million children worldwide are exposed to IPV each year (Pinheiro, ). The consequences of exposure can be severe and long‐lasting. Research has linked IPV exposure in childhood to impaired neurological, physiological, and psychosocial functioning that contribute to a wide‐range of health consequences. Indeed, IPV exposure has

2019 Campbell Collaboration

179. Diagnosis and Treatment of Low Back Pain

to develop a guideline of this size and breadth, some explanation is needed as to the why or why not certain items can be found in the con- tent. ? Although opioids are addressed, it is in a limited fashion. The opioid crisis as we know it today was a phenomenon that reached crisis proportions af- ter the guideline was already in development. In the future, more substantial attention to this is- sue will be merited. ? This is the largest clinical guideline NASS has ever undertaken and four years (...) are written utilizing a standard language that indicates the strength of the recommendation. “A” recommendations indicate a test or intervention is “recommended”; “B” recom- mendations “suggest” a test or intervention and “C” recommendations indicate a test or intervention “may be considered” or “is an option.” “I” or “Insufficient Evidence” statements clearly indicate that “there is insufficient evidence to make a recommendation for or against” a test or intervention. Work group con- sensus statements

2020 North American Spine Society

180. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

1 2 ABC: Aberrant Behavior Checklist 3 ASD: autism spectrum disorder 4 ADHD: attention-deficit/hyperactivity disorder 5 AEs: adverse events 6 BR: bedtime resistance 7 CAM: complementary and alternative medicine 8 CBT: cognitive behavioral therapy 9 CSHQ: Children’s Sleep Habit Questionnaire 10 CSHQ-BR: Children’s Sleep Habit Questionnaire-Bed Resistance 11 CSHQ-SOD: Children’s Sleep Habit Questionnaire-Sleep Onset Delay 12 DBC: Developmental Behavior Checklist 13 FDA: Food and Drug (...) and quality of life. 4 Poor sleep quality and insufficient 10 nighttime sleep can exacerbate core and associated ASD features, contributing to negative effects 11 on mood and emotional regulation, behavior, and cognitive functioning. Children and 12 adolescents with intellectual disabilities and severe symptoms associated with ASD are at 13 especially high risk for sleep problems. 5-7 Sleep disturbances are associated with communication 14 deficits and restrictive and repetitive behaviors in ASD. 8, 9

2020 American Academy of Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>